ABSTRACT
Human metaphase chromosomes A1 and A3 did bind more tritiated poly-L-lysine ([3H]PL) when they were isolated from lymphocyte cultures treated with LiCl rather than with NaCl or KCl. A2 chromosome did not show this differential behavior and in all three cases did bind more [3H]PL than the control A2 chromosome. The effect was dependent on the time of exposure of cells to the salts in tissue culture and on the degree of chromosomal contraction. The observed differences in [3H]PL binding are probably due to differences in surface morphology of the three chromosomes caused by treatment with alkali metal salts.
Subject(s)
Chromosomes, Human, 1-3/metabolism , Peptides/metabolism , Polylysine/metabolism , Cells, Cultured , Cesium/pharmacology , Chlorides/pharmacology , Chromosomes, Human, 1-3/drug effects , Humans , Lithium/pharmacology , Lymphocytes/metabolism , Mitosis , Potassium Chloride/pharmacology , Rubidium/pharmacology , Sodium Chloride/pharmacologySubject(s)
Chromosomes/drug effects , Imipramine/pharmacology , Lysine/metabolism , Macromolecular Substances/metabolism , Protein Binding , Binding Sites , Cells, Cultured/metabolism , Chromosomes, Human, 1-3/drug effects , Chromosomes, Human, 13-15/drug effects , Chromosomes, Human, 16-18/drug effects , Chromosomes, Human, 19-20/drug effects , Chromosomes, Human, 21-22 and Y/drug effects , Chromosomes, Human, 4-5/drug effects , Chromosomes, Human, 6-12 and X/drug effects , Humans , In Vitro Techniques , Isotope Labeling , Karyotyping , Lymphocytes/metabolism , Surface Properties , Time Factors , TritiumSubject(s)
Chromatids/drug effects , Chromosome Aberrations/drug effects , Isoniazid/pharmacology , Chromosomes, Human, 1-3/drug effects , Chromosomes, Human, 13-15/drug effects , Chromosomes, Human, 16-18/drug effects , Chromosomes, Human, 19-20/drug effects , Chromosomes, Human, 21-22 and Y/drug effects , Chromosomes, Human, 4-5/drug effects , Chromosomes, Human, 6-12 and X/drug effects , Humans , Sex Chromosomes/drug effectsSubject(s)
Bromodeoxyuridine/pharmacology , Chromosomes/drug effects , Hydroxylamines/pharmacology , Mitomycins/pharmacology , Analysis of Variance , Chromosomes, Human, 1-3/drug effects , Chromosomes, Human, 13-15/drug effects , Chromosomes, Human, 16-18/drug effects , Chromosomes, Human, 19-20/drug effects , Chromosomes, Human, 21-22 and Y/drug effects , Chromosomes, Human, 4-5/drug effects , Chromosomes, Human, 6-12 and X/drug effects , Constriction , Female , Humans , Leukocytes/cytology , Leukocytes/drug effects , Male , Methods , Sex Chromosomes/drug effects , Time FactorsSubject(s)
Chromosome Aberrations/drug effects , Cyclophosphamide/pharmacology , Chromosomes, Human, 1-3/drug effects , Chromosomes, Human, 13-15/drug effects , Chromosomes, Human, 16-18/drug effects , Chromosomes, Human, 19-20/drug effects , Chromosomes, Human, 21-22 and Y/drug effects , Chromosomes, Human, 4-5/drug effects , Chromosomes, Human, 6-12 and X/drug effects , Cyclophosphamide/therapeutic use , Female , Humans , Neoplasms/drug therapy , Sex Chromosomes/drug effectsABSTRACT
(3)H-actinomycin D, a guanine-binding agent, labels fixed human chromosomes nonrandomly. Actinomycin D added in G2 inhibits secondary constrictions and breaks chromosomes. There is some tendency for label to be concentrated at the ends of chromosomes and near the centromere. Labeling with (3)H-thymidine in the late stage of DNA synthesis shows a different pattern and in general lacks the telomeric concentrations. The sites of actinomycin D-induced breaks do not show good correspondence with the sites of actinomycin D label.